Which agent is a long-term disease-modifying therapy for multiple sclerosis?

Which agent is a long-term disease-modifying therapy for multiple sclerosis?

• A. Interferon beta-1a
• B. Glatiramer acetate
• C. Fingolimod
• D. Natalizumab

Answer: (A)

Long-term disease-modifying therapy for multiple sclerosis is about a treatment you take chronically to alter the underlying immune process, aiming to lower relapse rates and slow disability progression rather than just relieve acute symptoms. Interferon beta-1a fits this role well. It is a recombinant cytokine that modulates the immune response, dampening pro-inflammatory activity and reducing the movement of inflammatory cells into the central nervous system. Clinically, ongoing therapy with interferon beta-1a has been shown to lessen relapse frequency and MRI-detected disease activity, with a corresponding trend toward slower accumulation of disability over time. The other options are also disease-modifying therapies used long-term, but interferon beta-1a is a classic, well-established example that exemplifies the concept of chronic immune modulation in MS.

Long-term disease-modifying therapy for multiple sclerosis is about a treatment you take chronically to alter the underlying immune process, aiming to lower relapse rates and slow disability progression rather than just relieve acute symptoms. Interferon beta-1a fits this role well. It is a recombinant cytokine that modulates the immune response, dampening pro-inflammatory activity and reducing the movement of inflammatory cells into the central nervous system. Clinically, ongoing therapy with interferon beta-1a has been shown to lessen relapse frequency and MRI-detected disease activity, with a corresponding trend toward slower accumulation of disability over time. The other options are also disease-modifying therapies used long-term, but interferon beta-1a is a classic, well-established example that exemplifies the concept of chronic immune modulation in MS.